In an attempt to strengthen its pipeline, Madrigal has signed a license agreement with Pfizer for ervogastat, a clinical-stage oral diacylglycerol O-acyltransferase 2 (DGAT-2) inhibitor for in the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Through the deal, which includes US$50 M in upfront and near-term milestone payments, Madrigal aims to broaden the therapeutic potential of its own flagship drug, Rezdiffra (resmetirom), by planning to initiate a drug‑drug interaction study between the two therapies in 2026. This aligns with the company’s strategy to address significant unmet needs in liver and metabolic diseases, where effective treatment options remain limited.